Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Margaret Block (NPI 1184604118)

Field	Value
Entity Type	Individual
Organization	Margaret Block
Address	7500 Mercy Rd
City	Omaha
State	NE
ZIP	68124
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	January 17, 2006

Payer Source	Total Paid
Medicare	$1.7M
Medicaid	$0

Key Findings

Practice profile and service mix: As a Hematology & Oncology Physician, the provider’s claims are dominated by high-cost oncology injectables and associated infusion/E/M services, with J9271 (pembrolizumab) and J9144 (daratumumab) the top drug codes and multiple chemotherapy administration codes (96413, 96365, 96401, 96417) present on the top-25 list. The presence of supportive-care agents (J0897 denosumab, J0881 darbepoetin alfa, J1449 eflapegrastim, J1569 immune globulin) and tumor marker/lab testing (86300, 80053, 85025, 82378) further indicates a full-spectrum oncology infusion practice treating both solid tumor immunotherapy and hematologic indications. This mix is consistent with a clinic that provides on-site drug administration plus routine oncology monitoring.

Revenue concentration: Revenue is highly concentrated in a small set of Medicare codes — the precomputed top 3 Medicare codes account for 67.8% of this provider’s total Medicare revenue. Individually, J9271 accounts for $722.5K (43.8% of Medicare revenue), J9144 accounts for $294.1K (17.8%), and 99214 accounts for $101.7K (6.2%), showing the business is heavily dependent on a few high-revenue items. This concentration implies that changes in reimbursement or utilization for those specific drugs or services would materially affect overall revenue.

Payer mix and single-payor exposure: Lifetime Medicare revenue is $1.7M while Medicaid shows none on file, so this provider is effectively single-payer (Medicare) in the claims data available. That lack of Medicaid billing indicates limited state-program exposure and a dependence on Medicare policy and beneficiary volume for revenue stability, which is an operational and reimbursement concentration risk to monitor.

Competitive standing on top drug codes: For high-revenue oncology injectables the provider’s national ranks are in the middle of the peer distribution: J9271 ranks #566 of 1841 providers nationally (69th percentile; labeled typical, unremarkable volume) and J9144 ranks #320 of 615 providers nationally (46th percentile; labeled typical, unremarkable volume). These positions suggest the provider is a modest, regionally competitive participant for these expensive immunotherapy/oncology drugs rather than a national leader.

Exceptional E/M volume relative to peers: The office E/M code 99214 is an outlier for this provider — it generates $101.7K (6.2% of Medicare revenue) and the provider ranks #7199 of 479517 providers nationally (98th percentile; labeled extreme outlier, far above typical national volume for this code). That extreme percentile for 99214 indicates much higher-than-typical billing of moderate-complexity established-patient visits compared with national peers and may reflect either a high panel size, frequent follow-up cadence, or coding practice that yields elevated 99214 volume.

Ancillary and lab utilization: Multiple lab and monitoring codes appear in high national percentiles, including 86300 (rank #51 of 987, 95th percentile) and common panels CBC/CMP (85025 rank #1021 of 32833, 97th percentile; 80053 rank #826 of 26416, 97th percentile), each contributing nontrivial revenue. These placements indicate above-typical ordering of tumor markers and routine labs relative to peers, consistent with active management and monitoring of oncology patients and likely generating recurring ancillary revenue streams.

Operational tenure: The provider’s NPI was enumerated on 2006-01-17 (~20 years ago), indicating long-standing presence in the Medicare system. That tenure supports interpretation of patterns as established practice behavior rather than short-term spikes and suggests historical continuity in patient panel and service mix.

Implications for payers and downstream review: Given the dominant role of a few high-cost drug codes (top 3 = 67.8% of Medicare revenue) and the absence of Medicaid billing, payers should prioritize review of utilization and contract terms for J9271 and J9144 and monitor the unusually high 99214 volume for appropriateness and care pattern context. The combination of typical peer standing on expensive injectables but extreme E/M volume and high lab utilization suggests focused operational levers (visit frequency, lab ordering, drug mix) where care management or network strategies could meaningfully influence spend.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

62 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	16,800	$40	$722.5K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	7,740	$40	$294.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,200	$90	$101.7K
J0897	Injection, denosumab, 1 mg	5,340	$20	$96.1K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	3,430	$30	$92.7K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	2,400	$40	$86.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	500	$90	$46.7K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	19,310	$1	$38.6K
J1439	Injection, ferric carboxymaltose, 1 mg	30,000	$1	$30K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	360	$50	$19.1K

Showing 1–10 of 62

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 62 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Margaret Block — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

62 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	10	30	14,400	$40	$671.6K
J9144	8	10	10,440	$40	$434.6K
J1569	9	10	5,980	$40	$224.3K
J1449	4	10	3,700	$30	$92.4K
J0897	32	200	2,040	$20	$62.7K
J0881	5	10	17,260	$1	$54.5K
J1439	13	30	25,880	$1	$26.4K
J9217	32	50	110	$130	$20.6K
96413	7	80	60	$90	$18.2K
99214	48	3,210	110	$70	$14.9K

Showing 1–10 of 62

Related Providers

Other providers that share a Tax Identification Number (TIN) with Margaret Block, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Stefano Tarantolo	NE	Hematology & Oncology Physician	$3.2M	$0
Samuel Mehr	NE	Nuclear Medicine Physician	$2.5M	$0
Ralph Hauke	NE	Hematology & Oncology Physician	$2.5M	$0
Gamini Sooriyaarachchi	FL	Medical Oncology Physician	$2.2M	$0
Ryan Ramaekers	NE	Hematology & Oncology Physician	$2.1M	$0
Joel Michalski	NE	Internal Medicine Physician	$2M	$0
Yungpo Su	NE	Hematology & Oncology Physician	$1.9M	$0
Robert Langdon	NE	Hematology & Oncology Physician	$1.4M	$0
Muhammad Haroon	NE	Hematology & Oncology Physician	$1.4M	$0
Timothy Dorius	NE	Internal Medicine Physician	$1M	$0

Nearby Providers

Other providers in the same ZIP code as Margaret Block, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Alegent Health Bergan Mercy Health System	NE	General Acute Care Hospital	$0	$45.8M
Alegent Creighton Clinic	NE	Family Medicine Physician	$0	$43.2M
Childrens Home Healthcare	NE	Home Health Agency	$0	$40M
Maxim Healthcare Services, Inc.	NE	Home Health Agency	$0	$29.7M
Lutheran Family Services Of Ne, Inc	NE	Mental Health Counselor	$0	$5.8M
Epn Of Nebraska LLC	NE	Emergency Medicine Physician	$0	$5.6M
Pediatric Dental Specialists Of Greater Nebraska - Omaha, LLC	NE	Pediatric Dentistry	$0	$2.5M
Osc LLC	NE	Ambulatory Surgical Clinic/Center	$1.3M	$799.9K
Shoptikal LLC	NE	Eyewear Supplier	$0	$1.9M
House Enterprises Inc	NE	Emotionally Disturbed Childrens' Residential Treatment Facility	$0	$1.8M

Margaret Block — Billing Profile & Reimbursement Data

Sign up for Margaret Block — Billing Profile & Reimbursement Data policy alerts

Margaret Block — Billing Profile & Reimbursement Data

Sign up for Margaret Block — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References